At the news
? BULLISHIMPACT 8/10 8-K filed Feb 24, 2026 at 16:00 ET
Day One Biopharmaceuticals reported strong 2025 financial results with OJEMDA net product revenue of $155.4 million, representing 172% year-over-year growth. The company reaffirmed its 2026 U.S. net product revenue guidance of $225-$250 million, reflecting continued commercial momentum. R&D expenses decreased significantly year-over-year while prescription volume grew 181%, indicating strong market adoption.
- OJEMDA net product revenue was $155.4 million for full year 2025, up 172% year-over-year
- Fourth quarter 2025 revenue was $52.8 million
- Total prescriptions in 2025 were 4,635, representing 181% growth versus 2024
- Company reaffirmed 2026 U.S. net product revenue guidance of $225-$250 million
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access